A study focused on ovarian cancer found that myricetin inhibited the secretion of the angiogenesis mediator vascular endothelial growth factor (VEGF) and reduced the levels of p-Akt and hypoxia-inducible factor-1α (HIF-1α) proteins in ovarian cancer cells. This evidence concerns the gene AKT1 and ovarian cancer.